Caladrius Biosciences
Caladrius Biosciences is an American biopharmaceutical company active in the field of stem cell therapy and regenerative medicine, particularly (in 2012) of cardiovascular disease.[2]
 | |
| Type | Public |
|---|---|
| Nasdaq: CLBS Russell Microcap Index component | |
| Industry | Biopharmaceuticals |
| Headquarters | Basking Ridge, New Jersey[1], United States |
Key people | David J. Mazzo (CEO) |
| Website | caladrius |
Founded in 1980,[3] the company was formerly known as Corniche Group Inc, Phase III Medical Inc,[4] and NeoStem, Inc., it adopted its current name in 2015.[3]
Cardiovascular disease
In 2012 it started a phase 2 clinical trial of AMR-001 (NBS10), an autologous bone marrow-derived cell therapy enriched for CD34+ cells, for acute myocardial infarction.[5] Initial results included a statistically significant mortality benefit.[6]
References
- Editorial, Reuters. "CLBS.PH - Caladrius Biosciences Inc Profile | Reuters". www.reuters.comundefined.
{{cite web}}:|first1=has generic name (help) - NeoStem CEO Discusses Adult Stem Cell Therapies, May 14, 2012. Bloomberg Television. 3m35s video. Accessed September 2015.
- "Caladrius Biosciences - Consensus Indicates Potential 316.7% Upside - DirectorsTalk Interviews". Retrieved 2021-05-03.
- EDGAR Search Results – Neostem, EDGAR
- NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction (PreSERVE-AMI)
- Stem Cell Research Reveals Promising Data for Heart Attack Patients. Feb 2015
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.